Group One Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.03M Sell
3,100
-1,900
-38% -$647K ﹤0.01% 2695
2025
Q4
$1.99M Buy
5,000
+3,100
+163% +$1.37M ﹤0.01% 2289
2025
Q3
$866K Sell
1,900
-1,700
-47% -$692K ﹤0.01% 3176
2025
Q2
$1.17M Sell
3,600
-16,100
-82% -$4.45M ﹤0.01% 2612
2025
Q1
$5.32M Buy
19,700
+15,900
+418% +$4.09M 0.02% 1019
2024
Q4
$894K Sell
3,800
-3,500
-48% -$920K ﹤0.01% 2669
2024
Q3
$2.01M Buy
7,300
+3,600
+97% +$937K 0.01% 1708
2024
Q2
$899K Sell
3,700
-1,600
-30% -$253K ﹤0.01% 2076
2024
Q1
$792K Buy
5,300
+1,000
+23% +$167K ﹤0.01% 2296
2023
Q4
$823K Sell
4,300
-20,700
-83% -$3.53M ﹤0.01% 2646
2023
Q3
$4.43M Buy
25,000
+13,700
+121% +$2.61M 0.01% 1017
2023
Q2
$2.15M Sell
11,300
-100
-0.9% -$19.8K 0.01% 1654
2023
Q1
$2.28M Sell
11,400
-75,000
-87% -$15.8M 0.01% 1421
2022
Q4
$20.5M Sell
86,400
-22,500
-21% -$4.8M 0.05% 399
2022
Q3
$21.8M Sell
108,900
-51,200
-32% -$9.77M 0.04% 357
2022
Q2
$23.4M Buy
160,100
+76,600
+92% +$10.9M 0.04% 411
2022
Q1
$13.6M Buy
83,500
+20,600
+33% +$3.14M 0.01% 809
2021
Q4
$10.7M Sell
62,900
-21,400
-25% -$3.98M 0.01% 1060
2021
Q3
$15.9M Sell
84,300
-20,900
-20% -$3.92M 0.02% 750
2021
Q2
$17.8M Buy
105,200
+97,300
+1,232% +$14.3M 0.02% 703
2021
Q1
$1.11M Sell
7,900
-19,800
-71% -$2.98M ﹤0.01% 3102
2020
Q4
$3.6M Buy
27,700
+23,100
+502% +$3.08M 0.01% 1548
2020
Q3
$670K Sell
4,600
-18,400
-80% -$2.61M ﹤0.01% 2586
2020
Q2
$3.41M Sell
23,000
-19,000
-45% -$2.56M 0.02% 1070
2020
Q1
$4.57M Sell
42,000
-112,200
-73% -$13M 0.04% 575
2019
Q4
$17.8M Buy
154,200
+34,500
+29% +$3.44M 0.12% 178
2019
Q3
$9.63M Buy
119,700
+114,800
+2,343% +$9.08M 0.08% 287
2019
Q2
$356K Sell
4,900
-1,700
-26% -$130K ﹤0.01% 2441
2019
Q1
$617K Sell
6,600
-8,500
-56% -$711K 0.01% 1781
2018
Q4
$1.1M Sell
15,100
-61,300
-80% -$4.71M 0.01% 1435
2018
Q3
$6.69M Buy
76,400
+52,900
+225% +$5.32M 0.05% 440
2018
Q2
$2.31M Sell
23,500
-49,600
-68% -$4.92M 0.02% 1027
2018
Q1
$8.71M Buy
73,100
+16,500
+29% +$2.13M 0.09% 265
2017
Q4
$7.19M Sell
56,600
-135,700
-71% -$17.1M 0.05% 455
2017
Q3
$22.6M Buy
192,300
+96,000
+100% +$8.19M 0.21% 91
2017
Q2
$7.68M Buy
96,300
+41,800
+77% +$2.67M 0.08% 298
2017
Q1
$2.79M Buy
54,500
+100
+0.2% +$4.62K 0.03% 658
2016
Q4
$2.04M Sell
54,400
-18,700
-26% -$783K 0.02% 911
2016
Q3
$4.96M Buy
73,100
+13,100
+22% +$924K 0.05% 417
2016
Q2
$3.33M Buy
60,000
+34,000
+131% +$2.14M 0.04% 559
2016
Q1
$1.63M Buy
26,000
+11,500
+79% +$765K 0.02% 891
2015
Q4
$1.36M Sell
14,500
-19,700
-58% -$1.83M 0.02% 1101
2015
Q3
$2.75M Buy
34,200
+6,000
+21% +$667K 0.04% 610
2015
Q2
$3.38M Sell
28,200
-16,700
-37% -$2M 0.05% 474
2015
Q1
$4.69M Buy
44,900
+16,000
+55% +$1.62M 0.07% 275
2014
Q4
$2.8M Buy
28,900
+24,700
+588% +$2.29M 0.04% 480
2014
Q3
$328K Sell
4,200
-9,800
-70% -$632K 0.01% 1961
2014
Q2
$884K Sell
14,000
-5,700
-29% -$339K 0.01% 1223
2014
Q1
$1.32M Buy
19,700
+13,900
+240% +$1.08M 0.02% 881
2013
Q4
$373K Sell
5,800
-5,700
-50% -$340K 0.01% 1880
2013
Q3
$736K Sell
11,500
-4,200
-27% -$209K 0.01% 1258
2013
Q2
$487K Buy
+15,700
New +$418K 0.01% 1378

Other funds holding ALNY

Group One Trading's ALNY Position: Q1 2026 in Review

Group One Trading opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 5,545 shares worth $1.83M. The stake represents ﹤0.01% of the portfolio and ranks #2148 among its holdings. This is a return to the name: Group One Trading previously reported a position in ALNY as recently as Q2 2025.

Group One Trading first reported a position in ALNY in Q2 2013 and has held it in 29 quarters since. The position peaked at $9.07M in Q2 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Group One Trading held 5,545 shares of Alnylam Pharmaceuticals worth $1.83M as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Group One Trading position in Q1 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #2148 holding.
  • Group One Trading first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 29 quarters since.
  • Group One Trading's Alnylam Pharmaceuticals position peaked at $9.07M in Q2 2022.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.